Price (delayed)
$2.64
Market cap
$552.05M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.64
Enterprise value
$371.1M
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by
There are no recent dividends present for ALLO.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.